← Back to Search

Tech2Check for HIV Adherence (Tech2Check Trial)

N/A

Waitlist Available

Led By Allison Agwu, MD,ScM

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Eligible for antiretroviral therapy with viral load >20 copies/ml

Participants aged 12-25 years old diagnosed with HIV

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

Tech2Check Trial Summary

This trial is investigating whether a technology-enhanced community health nursing intervention can improve adherence to antiretroviral therapy and virologic suppression in young people living with HIV.

Who is the study for?

This trial is for English-speaking youth aged 12-25 living with HIV, who are aware of their status, eligible for ART, and have a viral load over 20 copies/ml. They must live in the Baltimore/Washington area or Jacksonville, Florida and be willing to consent to study procedures including randomization and follow-up.Check my eligibility

What is being tested?

The TECH2CHECK program is being tested against standard care to see if it improves adherence to antiretroviral therapy (ART) and virologic suppression in young people. It combines community health nursing with technology like SMS messaging.See study design

What are the potential side effects?

Since this trial focuses on improving medication adherence using technology and nursing support rather than testing new medications, side effects may not be directly related but could include privacy concerns or stress from increased monitoring.

Tech2Check Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am eligible for HIV treatment with a viral load over 20 copies/ml.

Select...

I am between 12 and 25 years old and have been diagnosed with HIV.

Tech2Check Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Viral suppression

Secondary outcome measures

Adherence to care as assessed by HRSA retention measure

Adherence to care as assessed by patient visits

Management Cost difference

Tech2Check Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment1 Intervention

TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.

Group II: ControlActive Control1 Intervention

Participants will receive standard of care.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Minority Health and Health Disparities (NIMHD)NIH

380 Previous Clinical Trials

1,215,534 Total Patients Enrolled

Johns Hopkins UniversityLead Sponsor

2,256 Previous Clinical Trials

14,819,951 Total Patients Enrolled

Allison Agwu, MD,ScMPrincipal InvestigatorJohns Hopkins University

Media Library

Tech2Check Clinical Trial Eligibility Overview. Trial Name: NCT03600103 — N/A

Human Immunodeficiency Virus Infection Research Study Groups: Control, Intervention

Human Immunodeficiency Virus Infection Clinical Trial 2023: Tech2Check Highlights & Side Effects. Trial Name: NCT03600103 — N/A

Tech2Check 2023 Treatment Timeline for Medical Study. Trial Name: NCT03600103 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what population is this medical experiment open for participation?

"This research is accepting 120 individuals aged 12-25 who have been diagnosed with HIV, and are cognizant of their status. These participants must meet the aforementioned age range requirements in order to join this trial."

Answered by AI

How many participants are enrolled in this clinical trial?

"Indeed, the clinical trial's page on clinicaltrials.gov indicates that it is actively searching for participants. The study began recruiting on July 11th 2018 and was recently updated on June 21st 2022; 120 patients across 3 sites are needed."

Answered by AI

Is there an ongoing recruitment program for this research project?

"As indicated on clinicaltrials.gov, this research is actively seeking enrollees. The trial was initially launched in July of 2018 and was refreshed as recently as June 21st 2022."

Answered by AI

Does this clinical trial permit participation from persons younger than 80 years old?

"This clinical trial has a specified age requirement of 12-25 years old. Additionally, there is 123 studies for minors and 411 studies targeting elderly patients."

Answered by AI

Recent research and studies

JMIR Research ProtocolsJournal

Recruitment of Youth Living with HIV to Optimize Adherence and Virologic Suppression: Testing the Design of Technology-based Community Health Nursing to Improve Antiretroviral Therapy (ART) Clinical Trials

Agwu, Allison Lorna, Hasiya Eihuri Yusuf, Lawrence D'Angelo, Mobeen Rathore, Jeanette Marchesi, Julia Rowell, Raina Smith, et al.. 2020. “Recruitment of Youth Living with HIV to Optimize Adherence and Virologic Suppression: Testing the Design of Technology-based Community Health Nursing to Improve Antiretroviral Therapy (ART) Clinical Trials”. JMIR Research Protocols. JMIR Publications Inc.. doi:10.2196/23480.

clinicaltrials.govStudy

Technology Based Community Health Nursing to Improve Combination Anti-Retroviral Therapy (cART) Adherence and Virologic Suppression in Youth Living With HIV

2018. "Technology Based Community Health Nursing to Improve Combination Anti-Retroviral Therapy (cART) Adherence and Virologic Suppression in Youth Living With HIV". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03600103.

All > Hiv Infection